Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David T Dunn

Showing results (51-60 of 77) with videos related to

Pageof 8
Sort By:
NEJM Evidence|August 15, 2022
Improving clinical trial interpretation with ACCEPT analysesMichelle N Clements, Ian R White, Andrew J Copas, et al.
Plos One|March 15, 2014
High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trialCissy Kityo, Diana M Gibb, Charles F Gilks, et al.
AIDS (London, England)|November 13, 2014
Long-term virological outcome in children on antiretroviral therapy in the UK and IrelandTrinh Duong, Ali Judd, Intira Jeannie Collins, et al.
Circulation|June 29, 2005
Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapyMarietta Charakida, Ann E Donald, Hannah Green, et al.
The Journal of Antimicrobial Chemotherapy|August 28, 2015
Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 cladesTomas Doyle, David T Dunn, Francesca Ceccherini-Silberstein, et al.
Antiviral Therapy|January 30, 2003
Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial)Diana M Gibb, A Sarah Walker, Steve Kaye, et al.
AIDS (London, England)|July 4, 2014
Phylogenetic analyses reveal HIV-1 infections between men misclassified as heterosexual transmissionsStéphane Hué, Alison E Brown, Manon Ragonnet-Cronin, et al.
BMC Infectious Diseases|February 23, 2017
The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial dataDavid I Dolling, Ruth L Goodall, Michael Chirara, et al.
BMC Public Health|July 25, 2024
Needs & networks: understanding the role and impact of social networks on HIV (self-)testing among GBMSM and trans people in England and WalesIsaac Yen-Hao Chu, Peter Weatherburn, Talen Wright, et al.
Eclinicalmedicine|February 16, 2024
Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)Nicholas I Paton, Wolfgang Stöhr, Alejandro Arenas-Pinto, et al.
Pageof 8

Showing results (51-60 of 77) with videos related to

Sort By:
Pageof 8
NEJM Evidence|August 15, 2022
Improving clinical trial interpretation with ACCEPT analysesMichelle N Clements, Ian R White, Andrew J Copas, et al.
Plos One|March 15, 2014
High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trialCissy Kityo, Diana M Gibb, Charles F Gilks, et al.
AIDS (London, England)|November 13, 2014
Long-term virological outcome in children on antiretroviral therapy in the UK and IrelandTrinh Duong, Ali Judd, Intira Jeannie Collins, et al.
Circulation|June 29, 2005
Early structural and functional changes of the vasculature in HIV-infected children: impact of disease and antiretroviral therapyMarietta Charakida, Ann E Donald, Hannah Green, et al.
The Journal of Antimicrobial Chemotherapy|August 28, 2015
Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 cladesTomas Doyle, David T Dunn, Francesca Ceccherini-Silberstein, et al.
Antiviral Therapy|January 30, 2003
Evolution of antiretroviral phenotypic and genotypic drug resistance in antiretroviral-naive HIV-1-infected children treated with abacavir/lamivudine, zidovudine/lamivudine or abacavir/zidovudine, with or without nelfinavir (the PENTA 5 trial)Diana M Gibb, A Sarah Walker, Steve Kaye, et al.
AIDS (London, England)|July 4, 2014
Phylogenetic analyses reveal HIV-1 infections between men misclassified as heterosexual transmissionsStéphane Hué, Alison E Brown, Manon Ragonnet-Cronin, et al.
BMC Infectious Diseases|February 23, 2017
The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial dataDavid I Dolling, Ruth L Goodall, Michael Chirara, et al.
BMC Public Health|July 25, 2024
Needs & networks: understanding the role and impact of social networks on HIV (self-)testing among GBMSM and trans people in England and WalesIsaac Yen-Hao Chu, Peter Weatherburn, Talen Wright, et al.
Eclinicalmedicine|February 16, 2024
Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)Nicholas I Paton, Wolfgang Stöhr, Alejandro Arenas-Pinto, et al.
Pageof 8